Clinical Commissioning Policy: Ustekinumab for refractory Crohn’s disease in pre-pubescent children

Ustekinumab is not recommended to be available as a routinely commissioned treatment option for refractory Crohn’s in pre-pubescent children. Access for older children will be provided in line with NHSE’s Commissioning Medicines for Children in Specialised Services Policy.


NHS England